Research and Markets: Global Uveitis Therapeutics Pipeline Review H2 2015

Research and Markets (http://www.researchandmarkets.com/research/nhgt4q/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with the latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects.

The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• 2-BBB Medicines BV
• AbbVie Inc.
• Aciont Inc.
• Aldeyra Therapeutics, Inc.
• Apitope International NV
• Bristol-Myers Squibb Company
• Can-Fite BioPharma Ltd.
• Clearside BioMedical, Inc.
• Effimune SAS
• Endocyte, Inc.
• Enzo Biochem, Inc.
• EyeGate Pharmaceuticals, Inc.
• HanAll Biopharma Co., Ltd.
• Icon Bioscience, Inc.
• IMMD Inc.
• Innomedica Ltd.
• Johnson & Johnson
• Kineta, Inc.
• Neuroptis Biotech
• Novartis AG
• Ocata Therapeutics, Inc.
• OncoNOx ApS
• Palatin Technologies, Inc.
• Panoptes Pharma Ges.m.b.H.
• Pfizer Inc.
• pSivida Corp.
• Regeneron Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.
• SynDevRx, Inc.
• ThromboGenics NV
• TxCell SA
• Virogenomics, Inc.
• XOMA Corporation

For more information visit http://www.researchandmarkets.com/research/nhgt4q/uveitis.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151127005352/en/